RxDoctor Payments Data

Lucy Saenz, MD

General Practice · Santa Ana, CANPI 1548367436

Payments from drug & device makers

$5,447in general payments, 2019–2025

Across 146 payments — averaging $37.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$996
  • Amgen$681
  • Novo Nordisk$657
  • Lilly USA, LLC$313
  • Amarin Pharma, Inc.$302
  • plus $605 from 6 others

What the payments were for

  • Food & beverage$5,33398%
  • Education$1142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,447 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$8,955
Medicare patients
32
Services billed
73

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol253$246,379
JardianceEmpagliflozin173$217,234
OzempicSemaglutide171$210,266
TrulicityDulaglutide55$96,509
JanuviaSitagliptin Phosphate71$73,923
EliquisApixaban37$40,896
VascepaIcosapent Ethyl74$36,041
JanumetSitagliptin Phos/Metformin Hcl32$25,806
MounjaroTirzepatide13$23,454
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$21,677
TradjentaLinagliptin21$20,200
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog19$8,920
Tresiba Flextouch U-100Insulin Degludec16$8,845
EdarbyclorAzilsartan Med/Chlorthalidone18$6,839
Lantus SolostarInsulin Glargine,hum.Rec.Anlog55$6,770

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,892$246,379253 claims
Boehringer IngelheimJardiance, Tradjenta$117$237,435194 claims
Novo NordiskOzempic$657$210,266171 claims
Lilly USA, LLCTrulicity, Mounjaro$313$119,96368 claims
PfizerEliquis$14$40,89637 claims
GSKTrelegy Ellipta, Arexvy, Shingrix$996$29,69252 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.

Other general practice in Santa Ana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →